BC
VRTX icon

Bridgefront Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Bridgefront Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-903
Closed -$354K – 800
2025
Q3 		$354K Buy
+903
New +$377K 0.1% 347
2025
Q1 		– Sell
-967
Closed -$389K – 868
2024
Q4 		$389K Buy
+967
New +$448K 0.13% 278
2022
Q3 		– Sell
-751
Closed -$212K – 471
2022
Q2 		$212K Buy
+751
New +$201K 0.24% 219
2021
Q4 		– Sell
-1,831
Closed -$332K – 460
2021
Q3 		$332K Buy
+1,831
New +$357K 0.35% 108

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Bridgefront Capital's VRTX Position: Q4 2025 in Review

Bridgefront Capital sold out of Vertex Pharmaceuticals (VRTX) in Q4 2025, closing a stake of 903 shares — an estimated $354K sold.

Bridgefront Capital first reported a position in VRTX in Q3 2021 and held it in 4 quarters. The position peaked at $389K in Q4 2024. 1,668 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

  • Bridgefront Capital reported no remaining Vertex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Bridgefront Capital sold 903 Vertex Pharmaceuticals shares in Q4 2025, an estimated $354K.
  • Bridgefront Capital first reported a position in Vertex Pharmaceuticals in Q3 2021 and held it in 4 quarters.
  • Bridgefront Capital's Vertex Pharmaceuticals position peaked at $389K in Q4 2024.
  • 1,668 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on Bridgefront Capital's 13F filing for Q4 2025, filed 13 Feb 2026.